HUALIN PHARMACEUTICAL-B WILL HOLD ITS ANNUAL GENERAL MEETING ON JUNE 27, 2024. THE REVIEW WILL INCLUDE THE AUDIT OF THE 2023 FINANCIAL STATEMENTS AND BOARD REPORTS, ELECTION OF DIRECTORS AND REMUNERATION, APPOINTMENT OF AUDITORS, ETC. The meeting will elect Mr. Chen Li, Ms. Zhang Yi, etc. as Executive Directors, and Mr. Robert Taylor NELSEN, Mr. Fangxin LI, and Mr. William Robert KELLER as Non-Executive Directors. In addition, the Board of Directors will be authorized to repurchase up to 10% of the issued shares and to issue no more than 20% additional shares. The Special Resolution includes the approval of the adoption of a third revised and recast of the Company's Articles of Association and Conditions. Shareholders are required to submit the proxy form by 25 June 2024.

HUALIN PHARMACEUTICAL-B WILL HOLD ITS ANNUAL GENERAL MEETING ON JUNE 27, 2024. THE REVIEW WILL INCLUDE THE AUDIT OF THE 2023 FINANCIAL STATEMENTS AND BOARD REPORTS, ELECTION OF DIRECTORS AND REMUNERATION, APPOINTMENT OF AUDITORS, ETC. The meeting will elect Mr. Chen Li, Ms. Zhang Yi, etc. as Executive Directors, and Mr. Robert Taylor NELSEN, Mr. Fangxin LI, and Mr. William Robert KELLER as Non-Executive Directors. In addition, the Board of Directors will be authorized to repurchase up to 10% of the issued shares and to issue no more than 20% additional shares. The Special Resolution includes the approval of the adoption of a third revised and recast of the Company's Articles of Association and Conditions. Shareholders are required to submit the proxy form by 25 June 2024.